- Home
- ISPR vs CRBP Comparison
ISPR vs CRBP Comparison
Compare ISPR & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ISPR | CRBP |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.8M | 147.4M |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ISPR | CRBP |
|---|---|---|
| Price | $1.73 | $9.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $7.50 | ★ $45.60 |
| AVG Volume (30 Days) | 156.0K | ★ 207.3K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $127,494,304.00 | $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.31 | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $1.44 | $5.23 |
| 52 Week High | $4.68 | $20.56 |
Technical Indicators
Market Signals| Indicator | ISPR | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 58.75 |
| Support Level | $1.53 | $9.86 |
| Resistance Level | $2.70 | $10.04 |
| Average True Range (ATR) | 0.22 | 0.68 |
| MACD | 0.03 | 0.11 |
| Stochastic Oscillator | 6.12 | 68.81 |
Price Performance
Historical ComparisonAbout ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping products in the United States, Europe, Canada, and South Africa. Geographically, the company generates the majority of its revenue from Europe.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.